Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples